CNR1 and Hepatic steatosis: Some of the beneficial clinical effects of the CB1 antagonist, SR141716A, have until recently been attributed both to the peripheral action of the molecule on adipose tissue [24,25,37,38], particularly with regard to weight loss and the increase in circulating adiponectin levels [17,24,25] and to the anti-inflammatory action of the molecule against hepatic steatosis and pro-atherosclerotic processes [16-19].